Erlotinib hydrochloride (ERL, Fig. 1A), a U.S. Food and Drug Administration‐approved drug, approved initially for NSCLC, is an epidermal growth factor receptor (EGFR) tyrosine kinase (TK) inhibitor. Here, EGFR is linked to non-small cell lung carcinoma.